Related Experiment Videos
Heart failure update
1Cardio.net Editorial Office, Macclesfield, Cheshire, UK. G.M.Porter@medschool.hull.ac.uk
Insights
The RUSSLAN study found levosimendan safe for post-infarction heart failure patients. This calcium sensitizing agent improved symptoms and survival, offering a unique option among intravenous inotropic treatments.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Post-infarction heart failure requires effective treatments.
- Intravenous inotropic support is often considered for these patients.
Purpose of the Study:
- To evaluate the safety and efficacy of levosimendan in patients with post-infarction heart failure.
- To assess levosimendan's impact on symptoms and survival.
Main Methods:
- The RUSSLAN study randomized 504 patients.
- Patients had post-infarction heart failure.
- Intravenous inotropic support was considered appropriate for participants.
Main Results:
- Levosimendan was safely administered in the absence of severe hypotension.
- The agent appeared to improve patient symptoms.
- Levosimendan showed potential for improving survival rates.
Conclusions:
- Levosimendan may be a safe and effective treatment for post-infarction heart failure.
- It offers a potentially unique therapeutic option among intravenous inotropes.
Abstract:
The RUSSLAN study, which randomised 504 patients with post-infarction heart failure in whom intravenous inotropic support might be deemed appropriate, was presented for the first time in a hotline session at the annual meeting of the Working Group on Heart Failure of the European Society of Cardiology. The study suggested that levosimendan, a new calcium sensitising agent, could be used safely in patients with post-infarction heart failure in the absence of severe hypotension and that it appeared to improve symptoms and survival. If these results can be confirmed it would render it unique among intravenous inotropic agents.